<DOC>
	<DOCNO>NCT01629758</DOCNO>
	<brief_summary>The purpose study determine whether combination 2 drug investigate ( IL-21 anti-PD-1 ) safe , provide preliminary information clinical benefit two different schedule combination .</brief_summary>
	<brief_title>Safety Study IL-21/Anti-PD-1 Combination Treatment Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms Site</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com All subject locally advance metastatic solid tumor For Part 2 ( Cohort Expansion ) : Tumor type restrict clear cell renal cell carcinoma ( ccRCC ) , nonsmall cell lung cancer ( NSCLC ) , melanoma At least 1 lesion measurable disease Only subject tumor sample PDL1 positive negative eligible Uncontrolled central nervous system ( CNS ) leptomeningeal metastasis Inadequate liver kidney function History autoimmune Disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>